Cargando…
Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant?
We present the case of an HIV-negative man in his 50s who developed a generalised nodular rash while having first-line bortezomib–cyclophosphamide–dexamethasone chemotherapy for multiple myeloma. The rash was biopsied and proven to be Kaposi’s sarcoma. The patient’s treatment was interrupted at the...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255255/ https://www.ncbi.nlm.nih.gov/pubmed/37263679 http://dx.doi.org/10.1136/bcr-2022-251044 |
_version_ | 1785056827289894912 |
---|---|
author | Farrugia, Daniel Sultana, Erika Babic, Darko Grech, Mark |
author_facet | Farrugia, Daniel Sultana, Erika Babic, Darko Grech, Mark |
author_sort | Farrugia, Daniel |
collection | PubMed |
description | We present the case of an HIV-negative man in his 50s who developed a generalised nodular rash while having first-line bortezomib–cyclophosphamide–dexamethasone chemotherapy for multiple myeloma. The rash was biopsied and proven to be Kaposi’s sarcoma. The patient’s treatment was interrupted at the sixth cycle of chemotherapy, by which time the rash had also spread to the oral mucosa and eyelid. The rash regressed spontaneously on stopping treatment. We were reluctant to restart myeloma treatment, but on the other hand, we wished to consolidate the very good partial response achieved. An autologous marrow transplant was done months later without any recurrence of his Kaposi’s with the initiation of bortezomib maintenance. Bortezomib has putative activity against Kaposi’s. The patient could benefit from imid-based (thalidomide, lenalidomide, pomalidomide) combination chemotherapy once his myeloma progresses or if there is a recurrence of Kaposi’s sarcoma. |
format | Online Article Text |
id | pubmed-10255255 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-102552552023-06-10 Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant? Farrugia, Daniel Sultana, Erika Babic, Darko Grech, Mark BMJ Case Rep Case Reports: Adverse drug reactions and complications We present the case of an HIV-negative man in his 50s who developed a generalised nodular rash while having first-line bortezomib–cyclophosphamide–dexamethasone chemotherapy for multiple myeloma. The rash was biopsied and proven to be Kaposi’s sarcoma. The patient’s treatment was interrupted at the sixth cycle of chemotherapy, by which time the rash had also spread to the oral mucosa and eyelid. The rash regressed spontaneously on stopping treatment. We were reluctant to restart myeloma treatment, but on the other hand, we wished to consolidate the very good partial response achieved. An autologous marrow transplant was done months later without any recurrence of his Kaposi’s with the initiation of bortezomib maintenance. Bortezomib has putative activity against Kaposi’s. The patient could benefit from imid-based (thalidomide, lenalidomide, pomalidomide) combination chemotherapy once his myeloma progresses or if there is a recurrence of Kaposi’s sarcoma. BMJ Publishing Group 2023-06-01 /pmc/articles/PMC10255255/ /pubmed/37263679 http://dx.doi.org/10.1136/bcr-2022-251044 Text en © BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ. |
spellingShingle | Case Reports: Adverse drug reactions and complications Farrugia, Daniel Sultana, Erika Babic, Darko Grech, Mark Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant? |
title | Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant? |
title_full | Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant? |
title_fullStr | Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant? |
title_full_unstemmed | Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant? |
title_short | Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant? |
title_sort | iatrogenic kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant? |
topic | Case Reports: Adverse drug reactions and complications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255255/ https://www.ncbi.nlm.nih.gov/pubmed/37263679 http://dx.doi.org/10.1136/bcr-2022-251044 |
work_keys_str_mv | AT farrugiadaniel iatrogenickaposissarcomafrominductiontherapyformyelomatotransplantornottotransplant AT sultanaerika iatrogenickaposissarcomafrominductiontherapyformyelomatotransplantornottotransplant AT babicdarko iatrogenickaposissarcomafrominductiontherapyformyelomatotransplantornottotransplant AT grechmark iatrogenickaposissarcomafrominductiontherapyformyelomatotransplantornottotransplant |